This is a guest post by Oliver Frost, data scientist at ImmoScout24, in partnership with Lukas Müller, AWS Solutions Architect. In 2010, ImmoScout24 released a price index for residential real estate in Germany: the IMX. It was based on ImmoScout24 listings. Besides the price, listings typically contain a lot of specific information such as the […]

TOKYO, Mar 7, 2022 - (JCN Newswire) - Fujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data. Leveraging the world's fastest supercomputer "Fugaku,"(1) the new technology enables high-speed calculation of 20,000 variables of data within a single day and allows for the discovery of previously unknown causal relationships relating to drug resistance in cancer cells from 1,000 trillion different possibilities.
Fujitsu and TMDU applied this technology to gene expression level(2) data obtained from cancer cell lines in order to analyze drug resistance(3) against anticancer drugs, and succeeded in extracting a new causal mechanism of a previously unknown gene that suggests a cause of resistance to lung cancer drugs. The new technology is expected to contribute to the acceleration of drug discovery and the realization of cancer therapies individualized for each patient.
The technology was developed under the theme of "elucidation of the cause and diversity of cancer using large-scale data analysis and AI technology," an initiative supported by TMDU, Kyoto University and Fujitsu as part of the supercomputer Fugaku achievement acceleration program(4).

Background

Even if a patient receives a targeted cancer drug(5) therapy, the appearance of drug-resistant cancer cells represents an ongoing threat to full remission. The mechanism for how certain cancers become drug resistant remains unclear, however, and researchers continue to work on new methods of analysis that shed light on how cells that have multiple driver mutations(6) acquire drug resistance. In drug development and clinical trials involving drug repositioning(7), it is important to identify patients for whom drugs are anticipated to have an effect. However, the effectiveness of drugs may differ depending on the organ and the individual and variations in gene expression, and the number of patterns combining expression levels of multiple genes exceeds 1,000 trillion(8). A comprehensive search of all 20,000 genes in the human genome would thus take more than 4,000 years with a conventional computer and finding ways to accelerate the process represents a major challenge.

Newly developed technology

Fujitsu implemented parallel conditional and causal algorithms to maximize computational performance with the supercomputer Fugaku to analyze the human genome within a timeframe needed for practical research. By utilizing Fujitsu's "Wide Learning"(9) AI technology to extract combinations of potential genes relating to the emergence of drug resistance based on statistical information, Fujitsu developed a novel technology that makes it possible to conduct a comprehensive search within a day.

Results

As a result of running data of the Dependency Map (DepMap)(10) portal using this technology on the supercomputer Fugaku, Fujitsu and TMDU were able to search the entire human genome for conditions and causality within a single day and determine the genes that cause resistance to drugs used to treat lung cancer(11).

Comment from Prof. Seiji Ogawa, Graduate School of Medicine, Kyoto University

Promising technologies like Fujitsu's AI technology for scientific discovery ("Wide Learning") may one day contribute to the discovery of biomarkers, which represent an area of growing interest in drug development. The key to the success of new drug development is to identify patients who are expected to benefit from new drugs and conduct clinical trials. If the marker that predicts who will benefit from the drug is known, the cost of clinical trials can significantly be reduced and the probability of success by conducting individual clinical trials can be increased. From this point of view, pharmaceutical manufacturers and others are expected to be very interested in this technology. The fact that it has been implemented using Fugaku has also raised expectations.

Future Plans

Moving forward, Fujitsu and TMDU will conduct a multilayered and comprehensive analysis that combines various data including time axis and location data with the aim of accelerating medical research, including in the field of drug efficacy, as well as to shed light on the causes of cancer.
Fujitsu and TMDU will also collaborate in experimental research in the fields of drug discovery and medicine. TMDU will further utilize the technology developed in this research to promote research on strategies for intractable diseases such as cancer.

In addition to medical care, Fujitsu will utilize the new technology to resolve challenges in a variety of fields, including marketing, system operations and manufacturing.

Acknowledgements
This research was conducted as part of Ministry of Education, Culture, Sports, Science and Technology's Fugaku Achievement Acceleration Program "Understanding the Origin and Diversity of Cancer through Large-scale Data Analysis and Artificial Intelligence Technologies" (JPMXP 1020200102). A part of the research was conducted with the computational resources of supercomputer Fugaku (Issue #: hp 200138, hp 210167).

(1) Supercomputer "Fugaku":
A computer installed at RIKEN as a successor to the supercomputer "K." From June 2020 to November 3, it ranked first in 4 categories in the supercomputer rankings for 4 consecutive years. Full operation started on March 9, 2021.
(2) Gene expression level :
Amount of RNA copied from DNA (the same nucleic acid as DNA synthesized by transcription using some DNA sequences as templates).
(3) Drug resistance :
A phenomenon in which the effect of a drug weakens while the drug is being administered.
(4) Supercomputer Fugaku Achievement Acceleration Program :
Program started in May 2020 by the Ministry of Education, Culture, Sports, Science and Technology with the aim to achieve early results.
(5) Targeted drug :
A drug designed to act only on the molecule (protein, gene, etc.) that is causing the disease.
(6) Driver mutations :
A genetic mutation that directly causes the development or progression of cancer.
(7) Drug repositioning :
The application of existing drugs developed and approved for the treatment of one disease to the treatment of another disease.
(8) More than 1,000 trillion :
Even if the expression level of each gene is restricted to a combination of 50 major genes known to be related to cancer and the expression level of each gene is classified into 2 categories (e.g., "high" or "low" gene expression), the condition number is 2 to the power of 50, which exceeds 1,000 trillion.
(9) Wide Learning :
Official site "Hello, Wide Learning!"
(10) Dependency Map (DepMap) :
Data on the sensitivity and resistance of approximately 4,500 drugs to approximately 600 different cancer cell lines, provided by the American Broad Institute. Mutation information of cancer cell lines and expression data of all genes are included.
(11) Fujitsu and TMDU analyzed gene expression data from DepMap of approximately 300 cancer cell lines, sensitivity and resistance data of Gefitinib (molecularly targeted drug used to treat lung cancer and other cancer types), and comprehensively searched for conditions and mechanisms of cancer cell lines that do not respond to Gefitinib. Fujitsu and TMDU identified conditions under which the expression levels of three transcription factors (genes that control gene transcription (synthesis of RNA)), ZNF516, E2F6, and EMX1, were low. In lung cancer cell lines that meet these conditions, a mechanism triggered by the transcription factors SP7 and PRRX1 was discovered as further potential causes of drug resistance in cancer cells (see reference image).

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
About Tokyo Medical and Dental University

Tokyo Medical and Dental University (TMDU) is Japan's only comprehensive medical university and graduate school, and has provided advanced medical treatment through a fusion of the medical and dental fields and worked to cultivate "professionals with knowledge and humanity." TMDU contributes to human health and the well-being of society by fostering outstanding healthcare professionals with a humane and global outlook.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comFujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data.

Written by: Aaron Vick | Muti-X Founder, Web3 Futurist, Technology Evangelist, Author of Inevitable Revolutions: Secrets and Strategies for a Successful Business & more NFT projects are amazing technological and behavioral case studies in feeding addictive behavior& gamifying the race to be early members of a project.  Why would anyone want to be early in the project? Well, for […]

More than $4 million have already been contributed to non-governmental organizations helping Ukraine from Russia’s unprovoked invasion of the country. A “crypto war,” according to analysts, has just begun. Meanwhile, as the panic of war depletes the country’s ATMs, many Ukrainians resort to Bitcoin. Elliptic, a blockchain analysis company in London, provided statistics on Friday…

The post A Crypto War Is Raging – Crypto Donations Fuel Russia-Ukraine War appeared first on Bitcoin News Miner.

Cryptocurrencies such as Bitcoin and Ethereum are traded on hundreds of various exchanges globally, and the price of a cryptocurrency on one exchange may differ from that on another exchange. Cryptocurrency arbitrage is a method in which traders purchase a cryptocurrency on one exchange and quickly sell that cryptocurrency for a higher price on another exchange.  This is where the old Wall Street tactic of ‘arbitrage’ comes into play. ‘Capturing the arb’ refers to profiting from the fact that an asset is selling for a low price in one exchange but a greater price in another. Traders use crypto arbitrage to take advantage of cryptocurrency’s lower price on one exchange by buying and selling it instantly for a higher price on another exchange.  Why are the Prices of Cryptocurrencies on Crypto Exchanges so Different? Centralized Exchanges The first thing to understand is that cryptocurrency pricing on centralized exchanges is determined by the order book’s most recent bid-ask matched order. So, the most recent price at which a trader buys or sells a digital asset on an exchange is termed the exchange’s real-time price. For example, if the most recently matched market order on an exchange is to buy bitcoin for $40,000, this price becomes the platform’s newest bitcoin price. The next matching order will determine the cryptocurrency price after that. Therefore, price discovery on exchanges is a constant process of deciding a cryptocurrency market price based on its most recent selling price. Decentralized Exchanges On the other hand, decentralized crypto exchanges utilize a different approach to price crypto assets. This is referred to as an ‘Automatic Market Maker’ approach since it relies on crypto arbitrage traders to keep prices consistent across exchanges. Decentral exchanges use liquidity pools rather than using an order book system to match buyers and sellers to trade cryptocurrencies at a specific price and volume. A separate pool must be set up for each cryptocurrency trading pair. What Are Different Types of Cryptocurrency Arbitrages? The most popular cryptocurrency arbitrage techniques used by crypto traders are discussed below: Deterministic Arbitrage This is the most common arbitrage technique. It entails traders purchasing and selling a digital asset on two exchanges at the same time to profit from market inefficiencies. The trader finds arbitrage opportunities on two different exchanges, buys the asset on the lower-priced platform, then sells the asset at a higher price on the higher-priced platform. Triangular Arbitrage It is also possible to profit from the uncorrelated pricing of three cryptocurrency pairs on an exchange, particularly if one of the cryptocurrencies is underpriced on the platform at the time. A trader may, for example, exchange BTC for ETH, convert ETH to SOL, and then trade SOL back to BTC. To summarise, this procedure entails shifting funds between BTC/ETH, ETH/SOL, and SOL/BTC combinations to accumulate more BTC. Decentralized Arbitration Traders use this approach to perform arbitrage trades on decentralized exchanges (DEXs) like Uniswap, Balancer, and Curve. Arbitrageurs can buy and sell pooled digital assets undervalued or overvalued on these various DEX platforms. These activities inevitably lead to price uniformity across Dexes like centralized crypto exchanges.   Statistical Arbitrage   This entails leveraging quantitative data models and algorithms to profit from large-scale arbitrage possibilities. Because the process is automated, an arbitrageur can make hundreds of deals in a matter of minutes, significantly increasing his or her profit potential.    Risks involved in Cryptocurrency Arbitrage  Losses   To be successful in crypto arbitrage, traders must execute trades fast so that they can profit from cryptocurrency price disparities across exchanges while they are still profitable.   A trader must be careful not to boost the buying price and decrease the selling price of a token by their own trades, especially in the thinly traded types of crypto that provide the widest spreads. Volume All crypto exchanges work similarly, and the pricing of crypto depends on the exchange’s most recent trade. It is important to remember that all trades are not made equal. Some trades happen with massive amounts of money, while others don’t trade with larger amounts. The trading volume on each influences the liquidity and accessible prices on a given exchange. Low volume could indicate that the exchange cannot execute a large enough trade to generate an investor’s profit. Low volume could also indicate that the trade is doable but will take too long to execute. Costs of Transactions Simultaneously, traders must watch the transaction fees associated with buying cryptocurrencies on different trading platforms. These fees will continue to fluctuate as the cryptocurrency markets develop, changing from exchange to exchange. Hacks & Fraud The cryptocurrency industry is mainly unregulated. There are also more chances of hacking, fraud, and monetary collapse. As a result, storing cryptocurrency safely is a hot topic among investors.

The post All you Should Know About Cryptocurrency Arbitrage appeared first on Cryptoknowmics-Crypto News and Media Platform.

DUBLIN–(BUSINESS WIRE)–The “Global Advanced Analytics Market by Component (Solutions and Services), Business Function (Sales & Marketing, Operations), Type (Big Data Analytics, Risk Analytics), Deployment Mode (On-premises and Cloud), Vertical and Region – Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering. The global Advanced Analytics market size to grow from USD 33.8 billion in […]

The post The Worldwide Advanced Analytics Industry is Expected to Reach $89.8 Billion by 2026 – ResearchAndMarkets.com appeared first on Fintech News.

To say that the capital market is complex would be an understatement. Only seasoned investors can reap lucrative returns from the volatile market in the long run. For laymen, trading and investment remain a gamble.  That doesn’t always have to be the case, though.  Quwiex helps investors step up their game with handpicked trading options […]

The post Quwiex Offers A Basket Of Trading Options For Investors To Take Advantage Of The Market appeared first on CryptoCoin.News.

According to multiple reports, a large-scale phishing scheme has targeted customers of Citibank, requesting victims to disclose sensitive personal details in order to lift alleged account holds. The campaign used emails that feature Citibank logos, sender addresses that look genuine at first, and typo-free content. The Citibank customers targeted in these attacks were informed that their […]

Get ready for this weekend’s pivotal European FNCS Semi-Finals. European competitive Fortnite players are mere days away from the most…

The post Fortnite FNCS Chapter 3 Season 1: EU Semi-Finals Preview & Predictions appeared first on Esports News Network | ESTNN.

The annual KLAS Healthcare IoT Security 2022 Performance report is based solely on feedback from vendor clients regarding the products and services vendors provide. Sensato is honored to receive...

(PRWeb February 22, 2022)

Read the full story at https://www.prweb.com/releases/sensato_achieves_a_high_score_from_clients_in_the_klas_healthcare_iot_security_report/prweb18506063.htm

Bitcoin bulls face a number of headwinds, ranging from dwindling demand on-chain, to over 4.7M BTC held at an unrealized loss. In this edition, we explore this potential sell-side energy carried by underwater investors.

HONG KONG, Feb 18, 2022 - (ACN Newswire) - Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global COVID-19 control. Recently, Omicron quickly spread in Japan and South Korea, and the number of newly confirmed cases in South Korea has exceeded 90,000 for two consecutive days. Although COVID-19 vaccine booster shots have been administered across the globe since 3Q2021, vaccine efficacy is shown to vary among vaccine products, and it is crucial to find and apply a vaccine with stronger protection against Omicron.

Livzon Pharmaceutical Group Inc. ("Livzon"), a long-established pharmaceutical company dedicated to research and development of innovative product, has developed a recombinant protein COVID-19 vaccine (the "V-01 vaccine") leveraging their recombinant protein technology platform since 2021.

It is reported that the V-01 vaccine is a COVID-19 recombinant protein vaccine jointly developed by Livzon MabPharm Inc. ("Livzon MAB") and the Institute of Biophysics, Chinese Academy of Sciences (the "Institute"). To date, Livzon MAB has conducted two global Phase III clinical trials in multiple countries, including (1) two doses of V-01 as basic immunization scheme, and (2) V-01 as a sequential booster for people who have received two doses of inactivated vaccine 3 to 6 months earlier. This is the only global Phase III clinical trial of sequential boosting immunization of the COVID-19 vaccine that have been approved by the regulatory authorities of multiple countries.

On February 16, Livzon has completed the interim analysis of the Phase III clinical trial for the sequential booster protocol, and released key data from this trial. According to the results disclosed, the person-year incidence rates of the V-01 sequential booster (after two doses of inactivated vaccine) group vs. the group who have only received two doses of inactivated vaccine were 6.73% and 12.80%, respectively, which showed a significant statistical difference (P=0.0012); and the absolute vaccine efficacy of the V-01 sequential booster was 61.35%, which is also shown to be significantly superior. The absolute vaccine efficacy after V-01 sequential booster has met World Health Organization's (WHO) standards.

Sixty valid genotype sequencing samples in this trial were confirmed to be Omicron using first-generation genotype sequencing of SARS-CoV-2 virus (the rest of samples are in the process of second-generation sequencing), indicating that V-01 sequential booster can produce good protection against Omicron infection. This is the first COVID-19 vaccine in the world of which the Phase III trial interim results have been disclosed since the Omicron outbreak.

Additionally, the Phase II trial results showed that V-01 had excellent immunogenicity and safety; and the overall incidence of adverse events was lower in the elder group than that of the younger adult group in comparison.
According to the company, the manufacturing of V-01 is well established in China with stable raw material supply and adequate reserves, ready to provide for global market once launched. The production line of Livzon MAB has been approved by the Guangdong Food and Drug Administration, and the vaccine production license has been granted. It is also disclosed that a workshop with an annual bulk product capacity of 3.5 billion doses is up and running at Livzon MAB, and the annual production capacity of formulated product has reached 1.5 billion doses.

With 71.32 million confirmed infected cases and 5.85 million cumulative deaths worldwide, the development and application of a safe and effective COVID-19 vaccine is urgent as the virus is spreading and mutating rapidly. Livzon, as a member of the Chinese Vaccine Research and Development Team, is in the process of obtaining EUA (Emergency Use Authorization) and conditional marketing approval for V-01 vaccine domestically and abroad, so as to provide a more robust and clinical-proven option for continuous immunization boosting for general public and to contribute to the global pandemic control efforts.



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comGlobal pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19.